Bionxt Solutions Inc. Stock
Price
Target price
€0.15
€0.15
-2.180%
-0.0035
-2.180%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Bionxt Solutions Inc. Stock
A loss of -2.180% shows a downward development for Bionxt Solutions Inc..
So far the community has only identified positive things for Bionxt Solutions Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Bionxt Solutions Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
VANCOUVER, BC – September 26, 2024 ‐
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to report that the European Patent Office
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter